Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International Cohorts
Sharmin, S., Lefort, M., Andersen, J.B., Leray, E., Horakova, D., Havrdova, E.K., Alroughani, R., Izquierdo, G., Ozakbas, S., Patti, F., et al. (2021). CNS Drugs (35). p.1217–1232

Estimation of sample size in randomized controlled trials in multiple sclerosis studying annualized relapse rates: A systematic review
Poncet-Megemont, L., Pereira, B., Rollot, F., Sormani, M.P., Clavelou, P., and Moisset, X. (2021). Mult Scler p.13524585211052400

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
Lebrun-Frénay, C., Rollot, F., Mondot, L., Zephir, H., Louapre, C., Le Page, E., Durand-Dubief, F., Labauge, P., Bensa, C., Thouvenot, E., et al. (2021). JAMA Netw Open (4). p.e2128271

A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica
Giovannelli, J., Ciron, J., Cohen, M., Kim, H.-J., Kim, S.-H., Stellmann, J.-P., Kleiter, I., McCreary, M., Greenberg, B.M., Deschamps, R., et al. (2021). Ann Clin Transl Neurol (8). p.2025–2037

Cumulative effects of therapies on disability in relapsing multiple sclerosis
Rollot, F., Casey, R., Leray, E., Debouverie, M., Edan, G., Wiertlewski, S., Vukusic, S., and Laplaud, D.-A. (2021a). Mult Scler (27). p.1760–1770

Determinants of therapeutic lag in multiple sclerosis
Roos, I., Leray, E., Frascoli, F., Casey, R., Brown, J.W.L., Horakova, D., Havrdova, E.K., Debouverie, M., Trojano, M., Patti, F., et al. (2021a). Mult Scler (27). p.1838–1851

Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network
Iaffaldano, P., Lucisano, G., Butzkueven, H., Hillert, J., Hyde, R., Koch-Henriksen, N., Magyari, M., Pellegrini, F., Spelman, T., Sørensen, P.S., et al. (2021). Mult Scler (27). p.1543–1555

Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis
Roos, I., Leray, E., Casey, R., Horakova, D., Havrdova, E., Izquierdo, G., Madueño, S.E., Patti, F., Edan, G., Debouverie, M., et al. (2021b). Neurology (97). p.e869–e880

The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies
Andersen, J.B., Sharmin, S., Lefort, M., Koch-Henriksen, N., Sellebjerg, F., Sørensen, P.S., Hilt Christensen, C.C., Rasmussen, P.V., Jensen, M.B., Frederiksen, J.L., et al. (2021). Mult Scler Relat Disord (53). p.103012

Oral nomegestrol acetate and transdermal 17-beta-estradiol for preventing post-partum relapses in multiple sclerosis: The POPARTMUS study
Vukusic, S., Ionescu, I., Cornu, C., Bossard, N., Durand-Dubief, F., Cotton, F., Durelli, L., Marignier, R., Gignoux, L., Laplaud, D.-A., et al. (2021a). Mult Scler (27). p.1458–1463

Effects of Age and Disease Duration on Excess Mortality in Patients With Multiple Sclerosis From a French Nationwide Cohort
Rollot, F., Fauvernier, M., Uhry, Z., Vukusic, S., Bossard, N., Remontet, L., Leray, E., and OFSEP Investigators (2021b). Neurology (97). p.e403–e413

MRI to detect and localize the area postrema in multiple sclerosis: The role of 3D-DIR and 3D-FLAIR
Farges, V., Hannoun, S., Benini, T., Marignier, R., and Cotton, F. (2021). J Neuroimaging (31). p.701–705

Clinical failure of natalizumab in multiple sclerosis: Specific causes and strategy
Guery, D., Marignier, R., Durand-Dubief, F., Lavie, C., Pique, J., Guerrier, O., and Vukusic, S. (2021). Rev Neurol (Paris) p.S0035-3787(21)00583-X

Untreated patients with multiple sclerosis: A study of French expert centers
Moisset, X., Fouchard, A.-A., Pereira, B., Taithe, F., Mathey, G., Edan, G., Ciron, J., Brochet, B., De Sèze, J., Papeix, C., et al. (2021). Eur J Neurol (28). p.2026–2036

Update on brain MRI for the diagnosis and follow-up of MS patients
Brisset, J.-C., Vukusic, S., Cotton, F., and Imaging Group of the “Observatoire francais de la sclérose en plaques” (2021). Presse Med (50). p.104067

Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease
Ameli, R., Guttmann, C.R.G., Prieto, J.C., Rollot, F., Palotai, M., Vukusic, S., Marignier, R., Cotton, F., Group Members for OFSEP Imaging Working Group, COPIL of OFSEP, et al. (2021). J Neuroradiol (48). p.170–175

Comparison of SimoaTM and EllaTM to assess serum neurofilament-light chain in multiple sclerosis
Gauthier, A., Viel, S., Perret, M., Brocard, G., Casey, R., Lombard, C., Laurent-Chabalier, S., Debouverie, M., Edan, G., Vukusic, S., et al. (2021). Ann Clin Transl Neurol (8). p.1141–1150

MRI findings in blinded trials should be available to treating physicians - Yes
Vukusic, S., and Lebrun-Frenay, C. (2021). Mult Scler (27). p.812–813

Assessing long-term effectiveness of MS treatment - a matter of debate
Trojano, M., and Iaffaldano, P. (2021). Nat Rev Neurol (17). p.197–198

Pregnancy with multiple sclerosis
Vukusic, S., Michel, L., Leguy, S., and Lebrun-Frenay, C. (2021b). Rev Neurol (Paris) (177). p.180–194

Diagnostic value of bright spotty lesions on MRI after a first episode of acute myelopathy
Rabasté, S., Cobo-Calvo, A., Nistiriuc-Muntean, V., Vukusic, S., Marignier, R., Cotton, F., and OFSEP, NOMADMUS Study Group (2021). J Neuroradiol (48). p.28–36

Clinical Features and Risk of Relapse in Children and Adults with Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Cobo-Calvo, A., Ruiz, A., Rollot, F., Arrambide, G., Deschamps, R., Maillart, E., Papeix, C., Audoin, B., Lépine, A.F., Maurey, H., et al. (2021). Ann Neurol (89). p.30–41

Relapses in Patients Treated with High-Dose Biotin for Progressive Multiple Sclerosis
Mathais, S., Moisset, X., Pereira, B., Taithe, F., Ciron, J., Labauge, P., Dulau, C., Laplaud, D., De Seze, J., Pelletier, J., et al. (2021). Neurotherapeutics (18). p.378–386

Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network
Hillert, J., Magyari, M., Soelberg Sørensen, P., Butzkueven, H., Van Der Welt, A., Vukusic, S., Trojano, M., Iaffaldano, P., Pellegrini, F., Hyde, R., et al. (2021). Front Neurol (12). p.647811

Efficacy and Safety of Teriflunomide in Multiple Sclerosis across Age Groups: Analysis from Pooled Pivotal and Real-world Studies
Oh, J., Vukusic, S., Tiel-Wilck, K., Inshasi, J.S., Rog, D., Baker, D.P., Pyatkevich, Y., Poole, E.M., and Vermersch, P. (2021). J Cent Nerv Syst Dis (13). p.11795735211028780

Women’s Health in Multiple Sclerosis: A Scoping Review
Ross, L., Ng, H.S., O’Mahony, J., Amato, M.P., Cohen, J.A., Harnegie, M.P., Hellwig, K., Tintore, M., Vukusic, S., and Marrie, R.A. (2021). Front Neurol (12). p.812147